Get the Stockscreener App
13.75
0.77%
0.105
Pre-market:
13.07
-0.68
-4.95%
Benitec Biopharma Inc stock is traded at $13.75, with a volume of 33,112.
It is up +0.77% in the last 24 hours and down -10.37% over the past month.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
See More
Previous Close:
$13.64
Open:
$13.5
24h Volume:
33,112
Relative Volume:
0.79
Market Cap:
$339.00M
Revenue:
$59,000
Net Income/Loss:
$-21.81M
P/E Ratio:
-1.2555
EPS:
-10.9518
Net Cash Flow:
$-18.07M
1W Performance:
+15.16%
1M Performance:
-10.37%
6M Performance:
+22.55%
1Y Performance:
+186.46%
1-Day Range:
$13.50
$13.86
1-Week Range:
$11.49
$14.22
52-Week Range:
$5.08
$16.90
Benitec Biopharma Inc Stock (BNTC) Company Profile
Name
Benitec Biopharma Inc
Sector
Industry
Phone
(510) 780-0819
Address
3940 TRUST WAY, HAYWARD, CA
Compare BNTC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
13.75 | 339.00M | 59,000 | -21.81M | -18.07M | -10.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Sep-12-24 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Piper Sandler | Overweight |
| Oct-05-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Apr-20-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-26-16 | Downgrade | Maxim Group | Buy → Hold |
| Dec-31-15 | Reiterated | Maxim Group | Buy |
| Sep-16-15 | Reiterated | Maxim Group | Buy |
View All
Benitec Biopharma Inc Stock (BNTC) Latest News
(BNTC) Long Term Investment Analysis - news.stocktradersdaily.com
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year? - Yahoo Finance
Benitec Biopharma: An Under-The-Radar And Undervalued Gene Therapy Developer - Seeking Alpha
JMP Securities Boosts Benitec Biopharma (NASDAQ:BNTC) Price Target to $20.00 - Defense World
Benitec Biopharma (BNTC) Stock Price Target Increased Amid Promi - GuruFocus
Benitec stock price target raised to $20 at JMP Securities - Investing.com Australia
Benitec stock price target raised to $20 at JMP Securities By Investing.com - Investing.com India
Benitec Biopharma Inc. (NASDAQ:BNTC) Given Average Rating of “Buy” by Brokerages - Defense World
Q3 EPS Forecast for Benitec Biopharma Boosted by Analyst - Defense World
Suvretta capital management buys $211,736 in Benitec Biopharma shares By Investing.com - Investing.com Canada
Insiders Are Loving These 5 Tech and Biotech Stocks - 24/7 Wall St.
Discover the Top 5 Small-Cap Biotech Stocks in 2025 - Investing News Network
Top 5 Small-cap Biotech Stocks of 2025 - Nasdaq
Benitec Biopharma Inc. (NASDAQ:BNTC) Director Suvretta Capital Management, L Buys 900,000 Shares of Stock - MarketBeat
Benitec Biopharma completes stock and warrant offerings By Investing.com - Investing.com Australia
Suvretta capital purchases $11.7m in Benitec Biopharma shares By Investing.com - Investing.com India
Major Investment Alert: Benitec Biopharma Stock Purchase Shakes the Market! - TipRanks
Benitec Biopharma completes stock and warrant offerings - Investing.com India
Suvretta capital purchases $11.7m in Benitec Biopharma shares - Investing.com
Benitec Biopharma inks deal granting stock resale rights - Investing.com India
Benitec Biopharma inks deal granting stock resale rights By Investing.com - Investing.com Canada
Benitec Biopharma prices $30M securities offerings - MSN
Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering - GlobeNewswire
Benitec Biopharma prices 1.44M shares at $13.00 in underwritten offering - TipRanks
Benitec Biopharma Prices $30 Million Equity Offerings - MarketScreener
(BNTC) Trading Report - news.stocktradersdaily.com
Benitec Biopharma (NASDAQ:BNTC) Receives Buy Rating from HC Wainwright - Defense World
H.C. Wainwright maintains Buy on Benitec BioPharma stock By Investing.com - Investing.com Australia
H.C. Wainwright maintains Buy on Benitec BioPharma stock - Investing.com
Micron Technology, Nike, FedEx And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Benitec Biopharma Inc. (NASDAQ:BNTC) Short Interest Up 17.6% in February - Defense World
Benitec Biopharma stock soars to 52-week high of $16.2 By Investing.com - Investing.com Australia
Benitec Biopharma stock soars to 52-week high of $16.2 - Investing.com
Benitec reports progress in OPMD swallowing function study By Investing.com - Investing.com South Africa
Benitec Biopharma Reports Positive Interim Results For BB-301 Gene Therapy In OPMD Clinical Trial - RTTNews
Benitec Biopharma’s SWOT analysis: gene therapy stock shows promise in OPMD By Investing.com - Investing.com South Africa
Benitec Biopharma’s SWOT analysis: gene therapy stock shows promise in OPMD - Investing.com
Benitec Biopharma Announces Positive Interim Results for BB-301 - TipRanks
Benitec reports progress in OPMD swallowing function study - Investing.com India
Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference - The Manila Times
Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with ... - The Bakersfield Californian
Benitec Biopharma Reports Positive Interim Clinical Results - GlobeNewswire
Benitec stock holds $18 target, Market Outperform rating By Investing.com - Investing.com UK
Benitec Biopharma Inc. (NASDAQ:BNTC) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Benitec Biopharma Inc Stock (BNTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Benitec Biopharma Inc Stock (BNTC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Mar 26 '25 |
Buy |
13.00 |
900,000 |
11,700,000 |
8,793,245 |
| BUCHI J KEVIN | Director |
Feb 27 '25 |
Option Exercise |
3.86 |
51,813 |
199,998 |
103,910 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 23 '24 |
Buy |
10.98 |
27,502 |
301,972 |
7,981,725 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 24 '24 |
Buy |
11.25 |
20,018 |
225,202 |
7,999,455 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 03 '24 |
Buy |
9.60 |
42,000 |
403,200 |
7,957,365 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 20 '24 |
Buy |
10.22 |
27,436 |
280,396 |
7,920,175 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 19 '24 |
Buy |
9.73 |
14,000 |
136,220 |
7,895,815 |
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):